Anti-inflammatory dose doxycycline for the treatment of rosacea

References

• Wilkin J, Dahl M, Detmar M et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J. Am. Acad. Dermatol.50, 907–912 (2004).
   PubMed Web of Science ®Google Scholar
• Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed2, 43–47 (2003).
   PubMedGoogle Scholar
• Millikan LE. Rosacea as an inflammatory disorder: a unifying theory? Cutis73, 5–8 (2004).
   PubMed Web of Science ®Google Scholar
• Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am. Fam. Physician.66, 435–440 (2002).
   PubMed Web of Science ®Google Scholar
• Powell FC. Clinical practice. Rosacea. N. Engl. J. Med.352, 793–803 (2005).
   PubMed Web of Science ®Google Scholar
• Sobye P. Aetiology and pathogenesis of rosacea. Acta Derm. Venereol.30, 137–158 (1950).
   PubMedGoogle Scholar
• Berg M, Liden S. An epidemiological study of rosacea. Acta Derm. Venereol.69, 419–423 (1989).
   PubMed Web of Science ®Google Scholar
• Baldwin HE. Oral therapy for rosacea. J. Drugs Dermatol.5, 16–21 (2006).
   PubMedGoogle Scholar
• Oztas MO, Balk M, Ogus E et al. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin. Exp. Dermatol.28, 188–192 (2003).
   PubMed Web of Science ®Google Scholar
• Maatta M, Kari O, Tervahartiala T et al. Tear fluid levels of MMP-8 are elevated in ocular rosacea – treatment effect of oral doxycycline. Graefes Arch. Clin. Exp. Ophthalmol.244, 957–962 (2006).
   PubMed Web of Science ®Google Scholar
• Smith JR, Lanier VB, Braziel RM et al. Expression of vascular endothelial growth factor and its receptors in rosacea. Br. J. Ophthalmol.91, 226–229 (2007).
   PubMed Web of Science ®Google Scholar
• Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv. Ther.18, 237–243 (2001).
   PubMed Web of Science ®Google Scholar
• Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J. Am. Acad. Dermatol.51, 327–341 (2004).
   PubMed Web of Science ®Google Scholar
• Robinson TW. Demodex folliculorum and rosacea. A clinical and histological study. Arch. Dermatol.92, 542–544 (1965).
   PubMedGoogle Scholar
• Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J. Am. Acad. Dermatol.28, 443–448 (1993).
   PubMed Web of Science ®Google Scholar
• Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch. Dermatol. Res.283, 162–166 (1991).
   PubMed Web of Science ®Google Scholar
• Nally JB, Berson DS. Topical therapies for rosacea. J. Drugs Dermatol.5, 23–26 (2006).
   PubMedGoogle Scholar
• van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J. Am. Acad. Dermatol.56, 107–115 (2007).
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized Phase III studies. J. Am. Acad. Dermatol.48, 836–845 (2003).
   PubMed Web of Science ®Google Scholar
• Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int. J. Dermatol.36, 942–946 (1997).
   PubMed Web of Science ®Google Scholar
• Bakar O, Demircay Z, Yuksel M, Haklar G, Sanisoglu Y. The effect of azithromycin on reactive oxygen species in rosacea. Clin. Exp. Dermatol.32, 197–200 (2007).
   PubMed Web of Science ®Google Scholar
• Plewig G, Schopf E. Anti-inflammatory effects of antimicrobial agents: an in vivo study. J. Invest. Dermatol.65, 532–536 (1975).
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis74, 118–122 (2004).
   PubMed Web of Science ®Google Scholar
• Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J. Clin. Microbiol.44, 3213–3217 (2006).
   PubMed Web of Science ®Google Scholar
• Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch. Dermatol.132, 934–939 (1996).
   PubMed Web of Science ®Google Scholar
• Francke EL, Neu HC. Chloramphenicol and tetracyclines. Med. Clin. North Am.71, 1155–1168 (1987).
   PubMed Web of Science ®Google Scholar
• Passier A, Smits-van Herwaarden A, van Puijenbroek E. Photo-onycholysis associated with the use of doxycycline. Br. Med. J.329, 265 (2004).
   PubMed Web of Science ®Google Scholar
• Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin. Microbiol Rev.5, 387–399 (1992).
   PubMed Web of Science ®Google Scholar
• Nikolowski J, Plewig G. Oral treatment of rosacea with 13-cis-retinoic acid. Hautarzt32, 575–584 (1981).
   PubMed Web of Science ®Google Scholar
• Scheinfeld N, Bangalore S. Facial edema induced by isotretinoin use: a case and a review of the side effects of isotretinoin. J. Drugs Dermatol.5, 467–468 (2006).
   PubMedGoogle Scholar
• Bikowski JB, Goldman MP. Rosacea: where are we now? J. Drugs Dermatol.3, 251–261 (2004).
   PubMedGoogle Scholar
• Walker C, Webster G. A multicenter, double-blind, randomized trial to evaluate long-term anti-inflammatory dose doxycycline (40 mg) therapy: results of the lack of effect on bacterial flora. Presented at: Fall Clinical Dermatology Conference. Las Vegas, NV, USA, 7–11 October 2006.
   Google Scholar
• Golub LM, Schuler EK, Gallagher BM. New therapeutic uses for an old family of drugs: travels of a dental researcher from the lab to the university’s office of technology transfer and beyond. Technol. Health Care.4, 311–316 (1996).
   PubMedGoogle Scholar
• Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol.54, 258–265 (2006).
   PubMed Web of Science ®Google Scholar
• Jones D. Reactive oxygen species and rosacea. Cutis74(Suppl.) 17–20 (2004).
   PubMed Web of Science ®Google Scholar
• Jain A, Sangal L, Basal E, Kaushal GP, Agarwal SK. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol. Online J.8, 2 (2002).
   PubMedGoogle Scholar
• Akamatsu H, Asada M, Komura J, Asada Y, Niwa Y. Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline. Acta Derm. Venereol.72, 178–179 (1992).
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM, Ryan ME et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dent. Res.12, 12–26 (1998).
   PubMedGoogle Scholar
• Kim MH. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J. Cell Biochem.89, 529–538 (2003).
   PubMed Web of Science ®Google Scholar
• Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest. Ophthalmol. Vis. Sci.30, 1569–1575 (1989).
   PubMed Web of Science ®Google Scholar
• Sorsa T, Ding Y, Salo T et al. Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western-blot assessment with special reference to their cellular sources in periodontal diseases. Ann. NY Acad. Sci.732, 112–131 (1994).
   PubMed Web of Science ®Google Scholar
• Golub LM, Wolff M, Roberts S et al. Treating periodontal diseases by blocking tissue-destructive enzymes. J. Am. Dent. Assoc.125, 163–169 (1994).
   PubMed Web of Science ®Google Scholar
• Amin AR, Attur MG, Thakker GD et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc. Natl Acad. Sci. USA93, 14014–14019 (1996).
   PubMed Web of Science ®Google Scholar
• Li R, Luo X, Pan Q et al. Doxycycline alters the expression of inflammatory and immune-related cytokines and chemokines in human endometrial cells: implication in irregular uterine bleeding. Hum. Reprod.21, 2555–2563 (2006).
   PubMed Web of Science ®Google Scholar
• Oracea®, package insert. CollaGenex Laboratories, PA, USA (2006).
   Google Scholar
• CollaGenex Pharmaceuticals, Inc. Data on file.
   Google Scholar
• Del Rosso JQ, Webster GF, Jackson M et al. Two randomized Phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J. Am. Acad. Dermatol.56, 791–802 (2007).
   PubMed Web of Science ®Google Scholar
• Theobald K, Bradshaw M, Leyden J. Anti-inflammatory-dose doxycycline (40-mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Presented at: Winter Clinical Dermatology Conference. Kohala Coast, HI, USA, 12–16 January 2007.
   Google Scholar
• Fowler JF. Combined effect of anti-inflammatory dose doxycycline and metronidazole topical gel 1% in the treatment of rosacea. Presented at: 65th Annual Meeting of the American Academy of Dermatology. Washington, DC, USA, 2–6 February 2007.
   Google Scholar
• Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis48, 411–417 (1991).
   PubMed Web of Science ®Google Scholar
• Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed2, 234–235 (2003).
   PubMedGoogle Scholar
• Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch. Dermatol.139, 467–471 (2003).
   PubMedGoogle Scholar
• Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother.5, 5–13 (2004).
   PubMed Web of Science ®Google Scholar
• Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J. Am. Acad. Dermatol.51, 499–512 (2004).
   PubMed Web of Science ®Google Scholar
• Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J. Invest. Dermatol.86, 449–453 (1986).
   PubMed Web of Science ®Google Scholar
• Bonamigo RR, Bakos L, Edelweiss M, Cartell A. Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J. Eur. Acad. Dermatol. Venereol.19, 646–647 (2005).
   PubMed Web of Science ®Google Scholar
• Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch. Dermatol.130, 748–752 (1994).
   PubMedGoogle Scholar
• Afonso AA, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC. Tear fluid gelatinase B activity correlates with IL-1α concentration and fluorescein clearance in ocular rosacea. Invest. Ophthalmol. Vis. Sci.40, 2506–2512 (1999).
   PubMed Web of Science ®Google Scholar